0

Pranlukast hemihydrate

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP150821037
CAS150821-03-7
Structure
MDL NumberMFCD24539454
Molecular Weight490.51
InChI KeyMSXTUBJFNBZPGC-UHFFFAOYSA-N
Description≥98% (HPLC), white solid
SolubilityDMSO: ≥10 mg/mL; H2O: insoluble
Assay≥98% (HPLC)
Formwhite solid
Size5MG, 25MG
Storage Conditions−20°C
1

A Simple Blending With α-glycosylated Naringin Produces Enhanced Solubility and Absorption of Pranlukast Hemihydrate

Hiromasa Uchiyama, Kazunori Kadota, Akihito Nakanishi, Mahamadou Tandia, Yuichi Tozuka

Int J Pharm. 2019 Aug 15;567:118490.

PMID: 31271814

1

Improving Dissolution and Oral Bioavailability of Pranlukast Hemihydrate by Particle Surface Modification With Surfactants and Homogenization

Eun-Sol Ha, In-hwan Baek, Jin-Wook Yoo, Yunjin Jung, Min-Soo Kim

Drug Des Devel Ther. 2015 Jun 24;9:3257-66.

PMID: 26150699

1

Preparation of Drug Nanoparticle-Containing Microparticles Using a 4-fluid Nozzle Spray Drier for Oral, Pulmonary, and Injection Dosage Forms

Takuto Mizoe, Tetsuya Ozeki, Hiroaki Okada

J Control Release. 2007 Sep 11;122(1):10-5.

PMID: 17655963

1

Self-microemulsifying Drug-Delivery System for Improved Oral Bioavailability of Pranlukast Hemihydrate: Preparation and Evaluation

Myoung-Ki Baek, Jong-Hwa Lee, Young-Ho Cho, Hak-Hyung Kim, Gye-Won Lee

Int J Nanomedicine. 2013;8:167-76.

PMID: 23326192

1

α-Glucosyl Hesperidin Induced an Improvement in the Bioavailability of Pranlukast Hemihydrate Using High-Pressure Homogenization

Hiromasa Uchiyama, Yuichi Tozuka, Fusatoshi Asamoto, Hirofumi Takeuchi

Int J Pharm. 2011 May 30;410(1-2):114-7.

PMID: 21419200

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode